Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 13 · below the Ichimoku cloud · RSI 33 · MACD below its signal
| 3.87 | 52-week high | +469.12% |
| 0.9020 | Previous month high | +32.65% |
| 0.8400 | Previous week high | +23.53% |
| 0.8100 | R3 (classic) | +19.12% |
| 0.7800 | R2 (classic) | +14.71% |
| 0.7700 | Previous week low | +13.24% |
| 0.7500 | Previous day high | +10.29% |
| 0.7310 | Previous month low | +7.50% |
| 0.7250 | R1 (classic) | +6.62% |
| 0.6950 | Pivot | +2.21% |
| 0.6800 | Price now | |
| 0.6650 | Previous day low | −2.21% |
| 0.6400 | S1 (classic) | −5.88% |
| 0.6100 | S2 (classic) | −10.29% |
| 0.5550 | S3 (classic) | −18.38% |
| 0.4550 | 52-week low | −33.09% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $327.5K | 0.00% | 430.74K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RANI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.4 | 13.2 | -46.4 | 20.8 | 7.1 | -20.1 | 1.8 | 10.3 | -7.4 | -14.0 | −49.6% | ||
| 2025 | 1.5 | 10.1 | -17.6 | -11.9 | -49.6 | -8.1 | 4.3 | -4.9 | -2.0 | 340.0 | -27.3 | -15.6 | −1.5% |
| 2024 | 4.2 | 8.1 | -16.8 | 105.1 | -13.8 | -30.9 | -25.5 | 13.1 | -32.5 | 6.0 | -11.8 | -32.2 | −58.7% |
| 2023 | -6.9 | 14.8 | -18.1 | -8.9 | -13.2 | 1.0 | 3.9 | -11.2 | -42.8 | -9.9 | 1.0 | 67.7 | −43.7% |
| 2022 | 26.8 | -19.5 | -19.1 | -9.4 | -6.8 | -9.4 | 8.9 | -20.9 | 7.6 | -36.3 | 35.7 | -28.7 | −63.9% |
| 2021 | 67.6 | -3.4 | 29.1 | 28.9 | -44.8 | +48.6% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 20, 2026 | Imran Mir ADirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 0.69 per share. | 36K | $24.84K |
| Jul 16, 2026 | Imran TalatChief Executive Officer | Purchase at price 0.72 per share. | 35K | $25.19K |
| Mar 26, 2026 | Javadi Alireza Ph.D.Chief Technology Officer | Sale at price 0.78 per share. | 386 | $301 |
| Oct 22, 2025 | Imran Mir ADirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 2.09 per share. | 2.08M | $4.35M |
| Oct 20, 2025 | South Cone Investments L.P.Beneficial Owner of more than 10% of a Class of Security | Sale at price 2.41 - 2.77 per share. | 5.92M | $15.71M |
| Dec 26, 2024 | Imran TalatChief Executive Officer | Sale at price 1.41 per share. | 8K | $11.30K |
| Dec 12, 2024 | Mckinley KateOfficer | Purchase at price 1.67 per share. | 18K | $29.99K |
| Dec 8, 2024 | Imran TalatChief Executive Officer | Purchase at price 1.94 per share. | 10.3K | $19.97K |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Buy / hold / sell counts